Obesity and diabetes are considered risk factors for Renal Cell Carcinoma (RCC). We aimed to explore whether insulin resistance (IR) plays an independent role in the development of RCC.
In a hospital-based case-control study, we analyzed serum glucose, insulin, leptin and adiponectin levels among 60 incident RCC patients and 236 age- and gender-matched healthy controls. We assessed insulin resistance according to insulin levels, alone or controlled for diabetes mellitus (DM). An alternative measure of insulin resistance, such as the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) index, was also assessed with and without controlling for history of DM. We used logistic regression to estimate odds ratios (ORs) adjusted for possible confounders.
The positive association of DM and waist to hip ratio as a measure of obesity with RCC was evident in the data set. Insulin levels controlled or not controlled for DM, however, were inversely associated with the risk for RCC; notably, an approximately 40% higher risk was observed in the 1st tertile when compared with the 2nd and 3rd tertile levels of insulin resistance. Similar results were obtained when HOMA-IR was alternatively used. The inverse associations persisted and were even strengthened after controlling for potential confounding factors in multivariate analyses.
Our data suggest that insulin resistance may be inversely associated with RCC risk, independently of obesity, DM, lifestyle and hormonal confounding variables. Given the close interconnections among metabolic, inflammatory and immune pathways in RCC causation, it is difficult to infer which process actually initiates a pathologic cascade. The findings should be considered as preliminary data that need to be further confirmed in more appropriate study designs.
Adami HO, McLaughlin J, Ekbom A, et al, 1991 Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2: 307–314.
Lindblad P, Chow WH, Chan J, et al, 1999 The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 42: 107–112.
Cho E, Adami HO, Lindblad P, 2011 Epidemiology of Renal Cell Cancer. Hematol Oncol Clin N Am 25: 651–665.
Chow WH, Dong LM, Devesa SS, 2010 Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7: 245–257.
Godsland IF, 2009 Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond) 118: 315–332.
Tilg H, Moschen AR, 2006 Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6: 772–783.
Gil A, María Aguilera C, Gil-Campos M, Cañete R, 2007 Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity. Br J Nutr 98: Suppl 1: 121–126.
Bastard JP, Maachi M, Lagathu C, et al, 2006 Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokkine Netw 17: 4–12.
Wellen KE, Hotamisligil GS, 2005 Inflammation, stress, and diabetes. J Clin Invest 115: 1111–1119.
Spyridopoulos TN, Petridou ET, Skalkidou A, et al, 2007 Adiponectin levels are associated with renal carcinoma: A case-control study. Int J Cancer 120: 1573- 1578.
Spyridopoulos TN, Petridou ET, Dessypris N, et al, 2009 Inverse association of leptin levels with renal cell carcinoma: results from a case-control study. Hormones (Athens) 8: 39–46.
Fleming ID, Cooper JS, Henson DE, et al, 1997 AJCC cancer staging manual, Philadelphia: Lippincot-Raven; pp, 231–232.
Medeiros LJ, Jones EC, Aizawa S, et al, 1997 Grading of renal cell carcinoma: workgroup no. 2. Union internationale contre le cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 990–991.
Storkel S, Eble JN, Adlakha K, et al, 1997 Classification of renal cell carcinoma: workgroup no. 1. Union internationale contre le cancer (UICC) and the American joint committee on cancer (AJCC). Cancer 80: 987–989.
Kahn BB, Flier JS, 2000 Obesity and insulin resistance. J Clin Invest 106: 473–481.
Pischon T, Lahmann PH, Boeing H, et al, 2006 Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 118: 728–738.
Calle EE, Kaaks R, 2004 Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579–591.
Wolk A, Mantzoros CS, Andersson SO, et al, 1998 Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90: 911–915.
Hankinson SE, Willett WC, Colditz GA, et al, 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396.
Ma J, Pollak MN, Giovannucci E, et al, 1999 Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620–625.
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X, 1999 Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control study. J Natl Cancer Inst 91: 151–156.
Petridou E, Dessypris N, Spanos E, et al, 1999 Insulinlike growth factor-I and binding protein-3 in relation to childhood leukaemia. Int J Cancer 80: 494–496.
Giovannucci E, 2007 Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86: s836–842.
Petridou ET, Sergentanis TN, Antonopoulos CN, et al, 2011 Insulin resistance: an independent risk factor for lung cancer? Metabolism 60: 1100–1106.
Antoniadis Α, Petridou ET, Antonopoulos CN, et al, 2011 Insulin in relation to melanoma risk. Melanoma Res (Epub ahead of print).
Baratta R, Amato S, Patane G, et al, 2003 Adiponectin and leptin: relationship with the insulin resistance syndrome. Diabetes 52: A81.
Major JM, Pollak MN, Snyder K, Virtamo J, Albanes D, 2010 Insulin-like growth factors and risk of kidney cancer in men. Br J Cancer 103: 132–135.
Yuen JS, Akkaya E, Wang Y, et al, 2009 Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer. Mol Cancer Ther 8: 1448–1459.
Parker A, Cheville JC, Lohse C, Cerhan JR, Blute ML, 2003 Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol 170: 420–424.
Ahmad N, Keehn CA, Coppola D, 2004 The expression of insulin-like growth factor-I receptor correlates with Fuhrman grading of renal cell carcinomas. Hum Pathol 35: 1132–1136.
Sichani MM, Yazdi FS, Moghaddam NA, et al, 2010 Prognostic value of insulin-like growth factor-I receptor expression in renal cell carcinoma. Saudi J Kidney Dis Transpl 21: 69–74.
Blüher S, Mantzoros CS, 2009 Leptin in humans: lessons from translational research. Am J Clin Nutr 89: Suppl: 991–997.
Lichnovska R, Gwozdziewiczova S, Chlup R, Hřebiček J, 2005 Serum leptin in the development of insulin resistance and other disorders in the metabolic syndrome. Biomed Papers 149: 119–126.
About this article
Cite this article
Spyridopoulos, T.N., Dessypris, N., Antoniadis, A.G. et al. Insulin resistance and risk of renal cell cancer: a case-control study. Hormones 11, 308–315 (2012). https://doi.org/10.14310/horm.2002.1359
- Renal Cell Carcinoma
- Insulin resistance